• +1-646-491-9876
    • +91-20-67278686

    Search

    Secondary Hyperparathyroidism - Pipeline Review, H1 2017

    Secondary Hyperparathyroidism - Pipeline Review, H1 2017

    • Report Code ID: RW0001689378
    • Category Healthcare
    • No. of Pages 41
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Secondary Hyperparathyroidism - Pipeline Review, H1 2017, provides an overview of the Secondary Hyperparathyroidism (Hormonal Disorders) pipeline landscape.

    Secondary hyperparathyroidism is occurs when the parathyroid glands in neck produce too much parathyroid hormone (PTH) because calcium levels are too low. Symptoms include bone deformities, broken bones, swollen joints and chronic kidney failure. Treatment includes calcimimetic and hormone replacement therapy.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Secondary Hyperparathyroidism - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Secondary Hyperparathyroidism (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Secondary Hyperparathyroidism (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Secondary Hyperparathyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 1 and 4 respectively.

    Secondary Hyperparathyroidism (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Secondary Hyperparathyroidism (Hormonal Disorders).
    - The pipeline guide reviews pipeline therapeutics for Secondary Hyperparathyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Secondary Hyperparathyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Secondary Hyperparathyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Secondary Hyperparathyroidism (Hormonal Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Secondary Hyperparathyroidism (Hormonal Disorders).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Secondary Hyperparathyroidism - Overview
    Secondary Hyperparathyroidism - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Secondary Hyperparathyroidism - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Secondary Hyperparathyroidism - Companies Involved in Therapeutics Development
    Amgen Inc
    Deltanoid Pharmaceuticals Inc
    Mitsubishi Tanabe Pharma Corp
    OPKO Health Inc
    Shire Plc
    Secondary Hyperparathyroidism - Drug Profiles
    cinacalcet hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CTA-091 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CTAP-201 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DP-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    evocalcet - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    lunacalcipol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Secondary Hyperparathyroidism - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VS-105 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VS-110 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VS-411 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Secondary Hyperparathyroidism - Dormant Projects
    Secondary Hyperparathyroidism - Discontinued Products
    Secondary Hyperparathyroidism - Product Development Milestones
    Featured News & Press Releases
    Jan 31, 2017: Kyowa Hakko Kirin Announces Top-Line Results of Phase 3 Clinical Study of KHK7580 with Secondary Hyperparathyroidism in Japan
    Dec 01, 2015: Kyowa Hakko Kirin Announces Commencement of Phase 3 Clinical Study of KHK7580 in Patients with Secondary Hyperparathyroidism in Japan
    Oct 15, 2014: Deltanoid's DP001 (2MD) pharmaceutical demonstrated safe and effective in kidney failure patients on dialysis
    Aug 29, 2014: Kyowa Hakko Kirin Announces Commencement of Phase 2b Clinical Study of KHK7580 in Patients with Secondary Hyperparathyroidism in Japan
    Jun 27, 2013: Kyowa Hakko Kirin Files Application Seeking Approval For Additional Indication For Regpara Tablets 25mg And 75mg
    Mar 07, 2013: Health Canada Cautions Against Use Of Amgen's Sensipar In Children
    Feb 26, 2013: Amgen's Pediatric Clinical Trial Of Sensipar Suspended By FDA Following Death Of Patient
    Nov 03, 2012: Amgen Announces Results From Phase III EVOLVE Trial Of Sensipar/Mimpara In Patients With Secondary Hyperparathyroidism And Chronic Kidney Disease Receiving Dialysis
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Secondary Hyperparathyroidism, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Secondary Hyperparathyroidism - Pipeline by Amgen Inc, H1 2017
    Secondary Hyperparathyroidism - Pipeline by Deltanoid Pharmaceuticals Inc, H1 2017
    Secondary Hyperparathyroidism - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
    Secondary Hyperparathyroidism - Pipeline by OPKO Health Inc, H1 2017
    Secondary Hyperparathyroidism - Pipeline by Shire Plc, H1 2017
    Secondary Hyperparathyroidism - Dormant Projects, H1 2017
    Secondary Hyperparathyroidism - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Secondary Hyperparathyroidism, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Amgen Inc
    Deltanoid Pharmaceuticals Inc
    Mitsubishi Tanabe Pharma Corp
    OPKO Health Inc
    Shire Plc

    Request for Sample

    Report Url http://www.reportsweb.com//secondary-hyperparathyroidism-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//secondary-hyperparathyroidism-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//secondary-hyperparathyroidism-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments